RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin

RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin

Abstract Background Malignant Pleural Mesothelioma (MPM) is a rare but aggressive neoplasia that usually presents at advanced stages. Even though some advances have been achieved in the management of patients with MPM, this malignancy continuous to impose a deleterious prognosis for affected patient...

Full description

Bibliographic Details
Main Authors: Wendy Muñoz-Montaño, Sae Muñiz-Hernández, Alejandro Avilés-Salas, Rodrigo Catalán, Luis Lara-Mejía, Suraj Samtani-Bassarmal, Andres F. Cardona, Jorge Mendoza-Desión, Daniel Hernández-Cueto, Altagracia Maldonado, Guillermina Baay-Guzmán, Sara Huerta-Yepes, Oscar Arrieta
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Cancer
Subjects:
RRM1
ERCC1
Immunohistochemistry
Biomarkers
Mesothelioma
Online Access:https://doi.org/10.1186/s12885-021-08287-5

Internet

https://doi.org/10.1186/s12885-021-08287-5

Similar Items